{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:27:30Z","timestamp":1793636850666,"version":"4.5.1"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.thromres.2026.109856","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:00:21Z","timestamp":1790319621000},"page":"109856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Direct oral anticoagulants in venous thrombotic antiphospholipid syndrome: Residual confounding behind an apparent arterial signal"],"prefix":"10.1016","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-1873","authenticated-orcid":false,"given":"G\u00fcney","family":"Sar\u0131o\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2026.109856_bb0005","article-title":"Effectiveness and safety of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome and venous thrombosis: a retrospective cohort study","volume":"264","author":"Lind","year":"2026","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.thromres.2026.109856_bb0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"13","key":"10.1016\/j.thromres.2026.109856_bb0015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2026.109856_bb0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109856_bb0025","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2026.109856_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct Oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.thromres.2026.109856_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001018","article-title":"Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials","volume":"10","author":"Adelhelm","year":"2023","journal-title":"Lupus Sci. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:46:30Z","timestamp":1793634390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":7,"alternative-id":["S0049384826002756"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109856","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants in venous thrombotic antiphospholipid syndrome: Residual confounding behind an apparent arterial signal","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109856"}}